NovoCure Ltd — Director's Dealing 2022

Jan 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-01-03

Reporting Person: Burke William Patrick (Chief Human Resources Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-03	Ordinary Shares	M	17452	$11.46	Acquired	43669	Direct
2022-01-03	Ordinary Shares	S	2633	$75.96	Disposed	41036	Direct
2022-01-03	Ordinary Shares	M	9750	$7.15	Acquired	50786	Direct
2022-01-03	Ordinary Shares	S	919	$76.087	Disposed	49867	Direct
2022-01-03	Ordinary Shares	M	1402	$21.60	Acquired	51269	Direct
2022-01-03	Ordinary Shares	S	399	$76.03	Disposed	50870	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-03	Options to Buy Ordinary Shares	$11.46	M	17452	Disposed	2026-02-24	Ordinary Shares (17452.0)	Direct
2022-01-03	Options to Buy Ordinary Shares	$7.15	M	9750	Disposed	2027-02-21	Ordinary Shares (9750.0)	Direct
2022-01-03	Options to Buy Ordinary Shares	$21.6	M	1402	Disposed	2027-10-30	Ordinary Shares (1402.0)	Direct

Footnotes

F1: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke.

F2: On January 3, 2022, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke, Mr. Burke sold 919 shares in multiple trades at prices ranging from $76.00 to $76.09. The price reported above reflects the weighted average sale price. Mr. Burke hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.

F3: Fully vested as of the date hereof.